Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Update

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) saw a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 123,500 shares, a growth of 175.7% from the July 31st total of 44,800 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average daily volume of 13,700 shares, the short-interest ratio is currently 9.0 days.

Eupraxia Pharmaceuticals Trading Down 4.4 %

Shares of EPRX traded down $0.12 during midday trading on Thursday, hitting $2.50. The company had a trading volume of 8,030 shares, compared to its average volume of 17,138. The firm has a 50 day moving average price of $2.62. The stock has a market cap of $68.21 million and a PE ratio of -2.50. Eupraxia Pharmaceuticals has a 52 week low of $2.39 and a 52 week high of $5.58.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its earnings results on Wednesday, August 7th. The company reported ($0.17) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Raymond James raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, May 22nd.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

An institutional investor recently bought a new position in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC acquired a new stake in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 13,000 shares of the company’s stock, valued at approximately $34,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.